Orthofix Medical Inc. reported second quarter 2026 financial results for the period ended June 30, 2026, announcing a net loss of $15.8 million and non-GAAP adjusted EBITDA of $20.1 million. Reported net sales reached $210.9 million, reflecting 4% growth on a reported basis and 5% growth on a pro forma constant currency basis compared to the prior year period. The company raised its full-year 2026 guidance, increasing expected net sales to a range of $845 million to $855 million and adjusted EBITDA to $95 million to $98 million. Orthofix Medical Inc. operates in the medical technology industry, specializing in musculoskeletal solutions including spinal implants, biologics, limb reconstruction systems, and bone growth therapies.

Orthofix Medical Inc. expects average Medicare reimbursement rates for non-invasive bone growth stimulators (HCPCS codes E0747, E0748, and E0760) to return to levels in effect prior to May 18, 2026. This follows CMS guidance issued on July 1, 2026, which reversed previous billing and fee schedule changes triggered by the FDA reclassification of these devices from Class III to Class II. Orthofix Medical Inc. operates in the medical device industry, providing bone growth stimulators and related orthopedic solutions.

At its 2026 Annual Meeting of Shareholders held on June 10, 2026, Orthofix Medical Inc. shareholders approved Amendment No. 5 to the Company's Second Amended and Restated Stock Purchase Plan. This amendment increases the number of common shares available for issuance under the plan by 1,250,000 shares. Additionally, the meeting resulted in the election of eight directors for one-year terms, the approval of an advisory resolution regarding executive compensation, and the ratification of Ernst & Young LLP as the independent auditor for the 2026 fiscal year. Orthofix Medical Inc. is a medical technology company that develops and manufactures products for musculoskeletal and neurovascular care.